Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer.
OBJECTIVE
Early detection of prostate cancer by prostate specific antigen testing is subject to ongoing controversy. Thus, practical tests to improve or replace prostate specific antigen would be highly desirable. In diagnostic studies promising results were shown for myeloid related protein-14 in serum and urine. However, confirmation in longitudinal population based studies is needed.


METHODS
Incident prostate cancer cases (32) and controls (74) matched by age were identified during a 2-year followup of a longitudinal study. The group of cases was further complemented by a sample of 24 prostate cancer cases recruited before initiation of treatment from a clinical study. A commercially available test was used to analyze serum and urinary myeloid related protein-14 in blinded fashion.


RESULTS
In contrast to prostate specific antigen, serum and urinary myeloid related protein-14 could not significantly discriminate between prostate cancer cases and controls.


CONCLUSIONS
In our study neither serum nor urinary myeloid related protein-14 proved suitable to distinguish prostate cancer cases from controls. Overall myeloid related protein-14 performed much worse than prostate specific antigen and it does not seem useful to reduce false-positive findings of prostate specific antigen in the controversial range of 4 to 10 ng/ml.
Müller
Heiko
H
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany. h.mueller@dkfz-heidelberg.de
Haug
Ulrike
U
Rothenbacher
Dietrich
D
Stegmaier
Christa
C
Brenner
Hermann
H
D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism*; D040502:Calgranulin B / Q000378:metabolism*; D016022:Case-Control Studies; D015331:Cohort Studies; D042241:Early Diagnosis; D004797:Enzyme-Linked Immunosorbent Assay; D005069:Evaluation Studies as Topic; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000652:urine; D012372:ROC Curve; D012016:Reference Values; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D040502:Calgranulin B; D017430:Prostate-Specific Antigen